Health and Healthcare

Amgen : AMGN

All Amgen Articles

720 Articles

Chris Lange | Jan 28, 2015 at 11:00 AM EST

Short Sellers Starting to Gang Up on Biotech

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected…

Chris Lange | Jan 13, 2015 at 8:55 AM EST

Short Interest in Biotechs Signals Optimism

24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.

Jon C. Ogg | Dec 17, 2014 at 1:05 PM EST

Is a Biosimilar (Generic) Top Cancer Drug for You?

A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.

Chris Lange | Dec 10, 2014 at 10:00 AM EST

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top…

Chris Lange | Nov 26, 2014 at 11:07 AM EST

Mixed Readings For Biotech Short Interest

ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Nov 24, 2014 at 10:23 AM EST

Amgen Surprise, Discontinues Stomach Cancer Drug Study

ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes…

Chris Lange | Nov 12, 2014 at 8:40 AM EST

Biotech Short Interest Becomes Stock Specific (Updated)

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.

Lee Jackson | Oct 30, 2014 at 8:55 AM EDT

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to…

Jon C. Ogg | Oct 29, 2014 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, October 29, 2014.

Paul Ausick | Oct 27, 2014 at 4:33 PM EDT

Amgen Posts 52-Week High, Beats It Again After Earnings

Amgen reported better-than-expected third-quarter 2014 results after markets closed Monday afternoon.

Chris Lange | Oct 27, 2014 at 10:30 AM EDT

Biotech Short Interest Becomes Stock Specific

Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.

Jon C. Ogg | Oct 21, 2014 at 4:22 PM EDT

The Plan to Drive Amgen Shares Up Over 70%

Amgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the…

Lee Jackson | Oct 13, 2014 at 8:40 AM EDT

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech…

Chris Lange | Oct 10, 2014 at 10:10 AM EDT

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the…

Lee Jackson | Sep 29, 2014 at 8:30 AM EDT

3 Likely Biotech Buyout Candidates

A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could…

1 … 28 29 30 31 32 … 48

Amgen : AMGN

All Amgen Articles

Short Sellers Starting to Gang Up on Biotech

Short Interest in Biotechs Signals Optimism

Is a Biosimilar (Generic) Top Cancer Drug for You?

Are Investors Signaling Optimism in Biotechs Through Short Interest?

Mixed Readings For Biotech Short Interest

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Biotech Short Interest Becomes Stock Specific (Updated)

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

Amgen Posts 52-Week High, Beats It Again After Earnings

Biotech Short Interest Becomes Stock Specific

The Plan to Drive Amgen Shares Up Over 70%

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Short Interest in Biotech Becomes Company Specific

3 Likely Biotech Buyout Candidates

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Amgen : AMGN

All Amgen Articles

Short Sellers Starting to Gang Up on Biotech

Short Interest in Biotechs Signals Optimism

Is a Biosimilar (Generic) Top Cancer Drug for You?

Are Investors Signaling Optimism in Biotechs Through Short Interest?

Mixed Readings For Biotech Short Interest

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Biotech Short Interest Becomes Stock Specific (Updated)

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

Amgen Posts 52-Week High, Beats It Again After Earnings

Biotech Short Interest Becomes Stock Specific

The Plan to Drive Amgen Shares Up Over 70%

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Short Interest in Biotech Becomes Company Specific

3 Likely Biotech Buyout Candidates

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn’t Paid Capital-Gains Tax Since.

Social Security’s $184,500 Wage Cap Is Under Fire. Here’s Exactly Who Would Pay More

Featured Reads

Her Advisor Said Wait Until 70. At 66, She Chose Time to Enjoy Social Security Over an 8%-a-Year Raise.

He Sold Nothing in the 2022 Crash. He Swapped Into a Similar Fund for a Week, Booked $90,000 of Losses, and Hasn't Paid Capital-Gains Tax Since.